A Phase 1/2 interventional study of KP-100IT and Placebo in Spinal Cord Injuries, sponsored by Kringle Pharma, Inc.. Completed at 2 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Kringle Pharma, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for acute spinal cord injury. The study is conducted at two clinical sites in Japan.
2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.
This study's enrollment of 45 is above the median of 24 across 1,634 interventional studies indexed under Spinal Cord Injuries.
Browse Spinal Cord Injuries studies →Kringle Pharma, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
Drug: KP-100IT
Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
Drug: Placebo
Also known as: Hepatocyte Growth Factor, HGF
Number and degree of adverse events
Adverse events will be judged by general condition, vital sign, electrocardiogram, MRI, blood chemistry, hematology, urinalysis, cerebrospinal fluid examination, and antibody formation
Time frame: 24 weeks
Change of ASIA (American Spinal Injury Association) motor score from baseline at 24 weeks
Time frame: 24 weeks
Change of ASIA motor score from baseline at 12 weeks
Time frame: 12 weeks
Time-dependent change of ASIA motor score from baseline
Time frame: 24 weeks
Time-dependent change of ASIA sensory score from baseline
Time frame: 24 weeks
Time-dependent grade change of modified Frankel scale from baseline
Time frame: 24 weeks
Time-dependent change of P-100 concentration in plasma and cerebrospinal fluid
Time frame: 6 weeks
Ran from Jun 2014 to primary completion in Dec 2017, 41 months.
Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 41 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KP-100IT
Kringle Pharma, Inc.